Everything below concerns 强制降解. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| 保存温度 | 2 至 8 摄氏度 | 避免冻结，部分制剂允许短期室温 |
| 粉末外观 | 白色至类白色固体 | 吸湿后易结块 |
| 纯度检测方法 | 反相高效液相色谱 | 紫外检测，常用 214 纳米 |
| 分子量确认方法 | 液相色谱串联质谱 | 偏差通常以 ppm 表示 |
| 常见降解产物 | 氧化与脱酰胺变体 | 源自甲硫氨酸与天冬酰胺残基 |
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
== External links == The History of the Darcy–Weisbach Equation Archived 2011-07-20 at the Wayback Machine Darcy–Weisbach equation calculator Pipe pressure drop calculator Archived 2019-07-13 at the Wayback Machine for single phase flows. Pipe pressure drop calculator for two phase flows. Archived 2019-07-13 at the Wayback Machine Open source pipe pressure drop calculator. Web application with pressure drop calculations for pipes and ducts ThermoTurb – A web application for thermal and turbulent flow analysis
Cuprate of Tl–Ba–Ca The first series of the Tl-based superconductor containing one Tl–O layer has the general formula TlBa2Can−1CunO2n+3, whereas the second series containing two Tl–O layers has a formula of Tl2Ba2Can−1CunO2n+4 with n =1, 2 and 3. In the structure of Tl2Ba2CuO6 (Tl-2201), there is one CuO2 layer with the stacking sequence (Tl–O) (Tl–O) (Ba–O) (Cu–O) (Ba–O) (Tl–O) (Tl–O). In Tl2Ba2CaCu2O8 (Tl-2212), there are two Cu–O layers with a Ca layer in between. Similar to the Tl2Ba2CuO6 structure, Tl–O layers are present outside the Ba–O layers. In Tl2Ba2Ca2Cu3O10 (Tl-2223), there are three CuO2 layers enclosing Ca layers between each of these. In Tl-based superconductors, Tc is found to increase with the increase in CuO2 layers. However, the value of Tc decreases after four CuO2 layers in TlBa2Can−1CunO2n+3, and in the Tl2Ba2Can−1CunO2n+4 compound, it decreases after three CuO2 layers. Cuprate of Hg–Ba–Ca The crystal structure of HgBa2CuO4 (Hg-1201), HgBa2CaCu2O6 (Hg-1212) and HgBa2Ca2Cu3O8 (Hg-1223) is similar to that of Tl-1201, Tl-1212 and Tl-1223, with Hg in place of Tl. It is noteworthy that the Tc of the Hg compound (Hg-1201) containing one CuO2 layer is much larger as compared to the one-CuO2-layer compound of thallium (Tl-1201). In the Hg-based superconductor, Tc is also found to increase as the CuO2 layer increases. For Hg-1201, Hg-1212 and Hg-1223, the values of Tc are 94, 128, and the record value at ambient pressure 134 K (−139 °C), respectively, as shown in table below.
== Trigger mechanism == Insulin is synthesized and secreted in the beta cells of the islets of Langerhans. Once insulin is synthesized, the beta cells are ready to release it in two different phases. As for the first phase, insulin release is triggered rapidly when the blood glucose level is increased. The second phase is a slow release of newly formed vesicles that are triggered regardless of the blood sugar level. Glucose enters the beta cells and goes through glycolysis to form ATP that eventually causes depolarization of the beta cell membrane (as explained in Insulin secretion section of this article). The depolarization process causes voltage-controlled calcium channels (Ca2+) opening, allowing the calcium to flow into the cells. An increased calcium level activates phospholipase C, which cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate into Inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to receptor proteins in the membrane of the endoplasmic reticulum (ER). This releases (Ca2+) from the ER via IP3 gated channels, and raises the cell concentration of calcium even more. The influx of Ca2+ ions causes the secretion of insulin stored in vesicles through the cell membrane. The process of insulin secretion is an example of a trigger mechanism in a signal transduction pathway because insulin is secreted after glucose enters the beta cell and that triggers several other processes in a chain reaction.
On 15 October 1940, doses of penicillin were administered to two patients with bacterial endocarditis at the Presbyterian Hospital in New York City, Aaron Alston and Charles Aronson. They became the first persons to receive penicillin treatment in the United States. The Columbia team presented the results of their penicillin treatment of the four patients at the annual meeting of the American Society for Clinical Investigation in Atlantic City, New Jersey, on 5 May 1941. Their paper was reported on by William L. Laurence in The New York Times and generated great public interest.
Sources: en.wikipedia.org
=== AZFb === The AZFb subregion is located in the middle region of Yq11. Genes in this region have been found to support the growth and maturity of sperm and are critical for efficient progression of spermatogenesis. Common phenotypic manifestations of deletions in this region are spermatogenic arrest and azoospermia. There are multiple candidate genes in the AZFb region that have been shown to cause infertility in males: RNA Binding Motif Protein, Y-linked (RBMY), PTPN13-like, Y-linked (PRY), Chromosome Y Open Reading Frame 15 (CYorf15), Ribosomal Protein S4, Y-linked (RPS4Y1), Eukaryotic Translation Initiation Factor 1A, Y-linked (EIF1AY), Lysine Demethylase 5D (KDM5D), X Linked Kell Blood Group Precursor, Y-linked (XKRY), and Heat Shock Transcription Factor, Y-linked (HSFY).
== Current state of the industry == A tablet counter has become a standard in more than 30,000 sites in 35 countries (as of 2010) (including many non-pharmacy sites, such as manufacturing facilities that use a counting machine as a check for small items). During the 1990s through 2012, numerous new pharmacy automation products came to market. During this timeframe, counting technologies, robotics, workflow management software, and interactive voice recognition (IVR) systems for retail (both chain and independent), outpatient, government, and closed-door pharmacies (mail order and central fill) were all introduced. Additionally, the concept of scalability - of migrating from an entry-level product to the next level of automation (e.g., counting technology to robotics) - was introduced and subsequently launched a new product line in 1997. Pharmacists are transitioning to automation. As the industry evolves and customer expectations grow, automation is emerging as necessity rather than luxury. Especially for independent pharmacies, automation becomes a means of keeping up with the competition of large chain pharmacies.
==== Conclusions ==== As the cathode rays carry a charge of negative electricity, are deflected by an electrostatic force as if they were negatively electrified, and are acted on by a magnetic force in just the way in which this force would act on a negatively electrified body moving along the path of these rays, I can see no escape from the conclusion that they are charges of negative electricity carried by particles of matter. As to the source of these particles, Thomson believed they emerged from the molecules of gas in the vicinity of the cathode.
== History == MrMed was conceived in August 2020 when Devashish Singh and Saurab Jain noticed challenges in specialty medicines. Despite facing initial setbacks due to the COVID Delta wave in India, which prompted the founders and their team to prioritize community assistance, MrMed was officially launched in June 2021. The company launched its mobile app in March 2023 for access to speciality medicines for conditions such as cancer, transplants, kidney, or liver diseases. It also raised $500,000 in funding from the Tamil Nadu Emerging Sector Seed Fund (TNESSF) and angel investors. On 8 December 2025, the company announced a strategic partnership with the American multinational pharmaceutical company Eli Lilly to support the distribution of specialty medicines in India.
=== February === February 5, 2010: Canada Employment increased by 43,000 in January, all in part-time, pushing the unemployment rate down 0.1 percentage points to 8.3%. January marks the fourth employment gain in six months. Despite the recent increases, employment still remains 280,000 below the level of October 2008. Employment gains in January were driven by women aged 25 to 54 and youths. This was the first notable increase for youths since the start of the employment downturn in the fall of 2008. There were large increases in part-time employment in January, bringing it back to the level of six months earlier. Full-time employment was little changed in January, but has trended up over the last six months. January's increase was among private sector employees, while self-employment declined. Over the last six months, the number of private and public sector employees has been rising while self-employment has been little changed. The largest employment increases in January occurred in business, building and other support services, and retail and wholesale trade. These were partially offset by losses in professional, scientific, and technical services, as well as agriculture.
Sources: en.wikipedia.org
==== Progressive multiple sclerosis ==== In 2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years. In 2026, tolebrutinib, a BTK inhibitor, was approved for non-relapsing secondary MS in the EU. It reduces the activity of microglia, immune cells in the brain, as well as of B cells. New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval. It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS). Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
=== imzML === The imzML standard was proposed for mass spectrometry imaging data exchange in a standardized XML file based on the mzML ontology. It splits experimental data into XML and spectral data in a binary file. Both files are linked by a universally unique identifier.
Methaqualone is a sedative-hypnotic medication that was widely prescribed during the mid-20th century. It was marketed under various brand names, including Quaalude ( KWAY-lood) and Sopor, typically containing 300 mg of methaqualone per tablet. A combination drug known as Mandrax was sold primarily in Europe, containing 250 mg of methaqualone and 20 mg of diphenhydramine in a single tablet. Methaqualone belongs to the quinazolinone class of compounds. Its commercial production was discontinued in many countries during the mid-1980s due to widespread misuse, addiction, and associated public health concerns. However, methaqualone continues to be used as a recreational drug in certain places such as South Africa. In addition, methaqualone analogues with greater than 100-fold potency such as mephenaqualone have emerged as novel designer drugs in the late 2010s and early 2020s.
It is current practice to disclose the genotype at the time of diagnosis, particularly when the affected individual is at least of adolescent age. If the affected individual is a child or infant, it is generally up to the parents, often in conjunction with a psychologist, to decide when to disclose the diagnosis.
Sources: en.wikipedia.org
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。
该方法依据疏水性差异分离主峰与相关杂质，对缺失序列、氧化产物和脱酰胺变体具有较好分辨能力。流动相中加入离子对试剂可改善峰形。紫外检测在肽键吸收区工作，灵敏度足以支持常规放行检验。
加速条件可以放大多数化学降解，但聚集与界面诱导的变化对容器、摇动和温度历史更敏感。某些固态转变在短时高温下不一定出现。因此实时稳定性数据仍不可替代，加速结果一般只作为趋势参考。
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.